Table 3.
Univariate and multivariate analysis for survival in 80 NSCLC patients with LM
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| HR (95%CI) | P | HR (95%CI) | P | |
| Gender (female vs. male) | 0.950 (0.531 to 1.698) | 0.862 | ||
| Age (< 53.5 vs. ≥53.5) | 0.545 (0.301 to 0.987) | 0.043 | 0.492 (0.265 to 0.915) | 0.025 |
| KPS (< 80 vs. ≥80) | 1.298 (0.640 to 2.632) | 0.470 | ||
| GCS (15 vs. ≤14) | 1.126 (0.572 to 2.220) | 0.731 | ||
| Concurrent brain metastasis (yes vs. no) | 1.039 (0.585 to 1.846) | 0.895 | ||
| EGFR mutation (yes vs. no) | 0.288 (0.159 to 0.522) | 0.000 | 0.390 (0.186 to 0.820) | 0.013 |
| EGFR TKI after LM (yes vs. no) | 0.260 (0.138 to 0.487) | 0.000 | 0.549 (0.491 to 1.039) | 0.053 |
| WBRT (yes vs. no) | 0.565 (0.315 to 1.013) | 0.053 | 0.697 (0.373 to 1.306) | 0.260 |
| Chemotherapy (yes vs. no) | 0.873 (0.480 to 1.589) | 0.657 | ||
| Bevacizumab (yes vs. no) | 1.909 (0.677 to 5.386) | 0.222 | ||
Abbreviations: NSCLC non-small-cell lung cancer, KPS Karnofsky Performance Status, GCS Glasgow Coma Scale, EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitors, LM leptomeningeal metastasis, WBRT whole brain radiotherapy, Gy gray, HR hazard ratio, CI confidence interval